Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2002

View Archived Issues

New therapeutic approaches for renal cell carcinoma presented at the AUA meeting

Azole CRF1 antagonists presented by BMS

5-HT receptor ligands and their use in sleep disorders, etc.

Boehringer Ingelheim patents dual ligands of 5-HT and D4 receptors

Novel antiandrogens in the Yamanouchi pipeline

BMS patent describes DNA topoisomerase I inhibitors

Endocannabinoid receptor modulators identified by Lilly research team

Antifungal thiazolidinones discovered at Oxford GlycoSciences

Early clinical data for DRF-1042 presented at ASCO

Clinical data on one of Igeneon's cancer vaccine candidates discussed at ASCO meeting

Potent inhibitor of Jak family protein tyrosine kinases discovered at Merck

Orally bioavailable peptidomimetic rhinoviral protease inhibitor

Investigational HIV protease inhibitor submitted for review in Europe by BMS

Dual inhibition of FPP synthetase and IPP isomerase displayed by a new bisphosphonate

Phase I results support further development of ABX-EGF for cancer

LymphoRad targets B-cells and B-cell tumors and exerts antitumor activity in preclinical studies

ThGRF improves sleep parameters and daytime vigilance in insomnia

Cathepsin S inhibitors with potential application in MS

Single-dose palonosetron provides prolonged relief from CINV

MLN-518 enters phase I in AML

Second phase II trial for GVAX pancreatic cancer vaccine

Platelet-derived growth factor evaluated in periodontal disease

Adenosine Therapeutics receives grant to develop A2A adenosine receptor agonists for sepsis

Patient enrollment completed in phase II trial of BioBypass in peripheral vascular disease

Moli-1901 enters phase II development in cystic fibrosis

Start of phase I trial of NOX-700 in type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...